![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1383405
¸¸¼ºÁúȯ °ü¸® ½ÃÀå ¿¹Ãø(-2030³â) : À¯Çüº°, Áúȯ À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®Chronic Disease Management Market Forecasts to 2030 - Global Analysis By Type, Disease Type, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¸¸¼ºÁúȯ °ü¸® ½ÃÀåÀº 2023³â 63¾ï ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È CAGR 13.8%·Î ¼ºÀåÇØ 2030³â 156¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸¸¼ºÁúȯ °ü¸® ½ÃÀåÀº ´ç´¢º´, ½ÉÀ庴, ¾Ï°ú °°Àº Àå±âÀûÀÎ ºñ°¨¿°¼º °Ç° »óŸ¦ ´Ù·ç´Â ÇコÄÉ¾î ºÐ¾ßÀÔ´Ï´Ù. ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇØ ÀÌ·¯ÇÑ ÁúȯÀ» ¿¹¹æ, ¸ð´ÏÅ͸µ, Ä¡·áÇϱâ À§ÇÑ ´Ù¾çÇÑ Àü·«°ú ±â¼úÀ» Æ÷ÇÔÇÕ´Ï´Ù. ±× ¿ëµµ¿¡´Â ȯÀÚ ¿ø°Ý ¸ð´ÏÅ͸µ, ¸ÂÃãÇü Ä¡·á °èȹ, µ¥ÀÌÅÍ ±â¹Ý °³ÀÔ µîÀÌ Æ÷ÇԵ˴ϴÙ.
NCBI¿¡ µû¸£¸é, ¸¸¼ºÁúȯÀº »ç¸Á¿øÀÎÀÇ ¾à 60%, Àü ¼¼°è Áúº´ºÎ´ãÀÇ 43%¸¦ Â÷ÁöÇÕ´Ï´Ù.
Àα¸ Åë°è°¡ °í·ÉÃþÀ¸·Î À̵¿ÇÔ¿¡ µû¶ó ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸ Ãß¼¼´Â ÀÇ·á ½Ã½ºÅÛ°ú ÀÚ¿ø¿¡ Å« ºÎ´ãÀ» ÁֹǷΠÁúº´ °ü¸® Àü·«À» °ÈÇØ¾ß ÇÕ´Ï´Ù. ¸¸¼ºÁúȯ¿¡ ´ëÇÑ Àü¹®ÀûÀÎ Ä¡·á, ¿¹¹æ Á¶Ä¡ ¹× Àå±âÀûÀÎ Áö¿ø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸ÂÃãÇü ÇコÄÉ¾î ¼Ö·ç¼Ç ¹× ±â¼ú °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °í·ÉÈ »çȸÀÇ ÀÇ·á ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â °ÍÀº ³ëÀÎÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó È¿°úÀûÀ̰í È¿À²ÀûÀÎ Ä¡·á¸¦ Á¦°øÇÏ´Â µ¥ Á¡Á¡ ´õ Áß¿äÇØÁ® ¸¸¼ºÁúȯ °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
ÃÖ÷´Ü ±â¼ú, ¿ø°Ý ¸ð´ÏÅ͸µ ½Ã½ºÅÛ, °³ÀÎ ¸ÂÃãÇü Ä¡·á ¼Ö·ç¼ÇÀÇ °³¹ß ¹× µµÀÔ¿¡´Â ¸¹Àº ÀçÁ¤Àû ÅõÀÚ°¡ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÇ·á ±â°ü°ú ÀÇ·á ¼ºñ½º Á¦°øÀÚ´Â ¿¹»êÀÇ Á¦¾àÀ¸·Î ÀÎÇØ °í°¡ÀÇ ±â¼ú µµÀÔ¿¡ ÀÚ¿øÀ» ÇÒ´çÇÏ´Â µ¥ ¾î·Á¿òÀ» °ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ºñ¿ëÀ¸·Î ÀÎÇØ ȯÀÚµéÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ¿© °í±Þ ¸¸¼ºÁúȯ °ü¸®¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °æÁ¦Àû ºÎ´ãÀº ¼Ò±Ô¸ð ÀÇ·á ½Ã¼³°ú ÀÇ·á ¼ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀÌ Á¾ÇÕÀûÀÎ Áúº´ °ü¸® ¼ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µé¾î °Ç° °ÝÂ÷¸¦ ¾ÇȽÃų ¼ö ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ¸¸¼ºÁúȯ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ °øÆòÇÑ Á¢±ÙÀ» º¸ÀåÇϱâ À§Çؼ´Â ÀÌ·¯ÇÑ ºñ¿ë À庮À» ³·Ãß´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.
¼¼°èÀÇ ¸¹Àº Á¤ºÎ´Â ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇÑ °æÁ¦Àû, °øÁߺ¸°ÇÀû ¿µÇâÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Çõ½ÅÀûÀÎ Áúº´ °ü¸® ¼Ö·ç¼ÇÀÇ °³¹ß ¹× äÅÃÀ» Àå·ÁÇÏ´Â Á¤Ã¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. Àμ¾Æ¼ºê¿¡´Â ÀÇ·á ½Ã½ºÅÛ¿¡ ±â¼ú°ú ¿ø°Ý ÀÇ·áÀÇ ÅëÇÕÀ» ÃËÁøÇϰí ÀÇ·á ¼ºñ½º Á¦°øÀÚ°¡ È¿°úÀûÀÎ ¸¸¼ºÁúȯ °ü¸® ¼ºñ½º¸¦ ½±°Ô Á¦°øÇÒ ¼ö ÀÖµµ·Ï ÀçÁ¤ Áö¿ø, »óȯ ÇÁ·Î±×·¥, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Á¤Ã¥Àº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀÇ·á Á¢±Ù¼º Çâ»ó, ÀÇ·áºñ Àý°¨, ȯÀÚ °á°ú °³¼±¿¡ ±â¿©ÇÏ¿© ÀÇ·á ÀÌÇØ°ü°èÀÚ¿Í È¯ÀÚ ¸ðµÎ¿¡°Ô À©-À©(Win-Win) ½Ã³ª¸®¿À¸¦ âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù.
±ÔÁ¦´Â ȯÀÚÀÇ ¾ÈÀü°ú µ¥ÀÌÅÍ º¸¾ÈÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀÌÁö¸¸, Áö³ªÄ¡°Ô º¹ÀâÇϰí Á¦ÇÑÀûÀÎ ±ÔÁ¦ ȯ°æÀº Çõ½ÅÀ» ÀúÇØÇÏ°í ¸¸¼ºÁúȯ °ü¸®¸¦ À§ÇÑ »õ·Î¿î ±â¼ú°ú ¼Ö·ç¼ÇÀÇ ½Å¼ÓÇÑ °³¹ß ¹× ¹èÆ÷¸¦ ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ Áؼö ¹®Á¦´Â Á¦Ç° Ãâ½Ã¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ëÀ» Áõ°¡½ÃÄÑ ±â¾÷°ú ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿¡°Ô À庮ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¹ÀâÇÑ ±ÔÁ¦ ȯ°æÀ» ±Øº¹ÇÏ´Â °ÍÀº ½ÃÀå ÁøÀÔÀ» ÁÖÀúÇÏ°Ô Çϰí, °æÀïÀ» Á¦ÇÑÇϸç, ÷´Ü ¸¸¼ºÁúȯ °ü¸® ¼Ö·ç¼ÇÀÇ »ç¿ëÀ» Á¦ÇÑÇÏ¿© ±Ã±ØÀûÀ¸·Î ȯÀÚ Ä¡·á¿Í ÀÇ·á ½Ã½ºÅÛÀÇ È¿À²¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
COVID-19ÀÇ À¯ÇàÀº ¸¸¼ºÁúȯ °ü¸® ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Àü¿°º´ ´ëÀÀ¿¡ ÁýÁßÇÏ¸é¼ ÀÏ»óÀûÀÎ ¸¸¼ºÁúȯ °ü¸®¿¡ È¥¶õÀÌ »ý±â°í ÀÖ½À´Ï´Ù. ´ë¸é Áø·á¸¦ ÃÖ¼ÒÈÇϰí Ãë¾à °èÃþÀÇ ³ëÃâ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í °ü·Ã ³ë·Â¿¡ ÀÚ¿øÀÌ ÁýÁßµÇ¸é¼ ÀÏ»óÀûÀÎ °ËÁø ¹× Ä¡·á°¡ Áö¿¬µÇ¾î °ü¸®µÇÁö ¾Ê´Â ¸¸¼ºÁúȯÀÌ Áõ°¡ÇÏ¿© Àå±âÀûÀÎ °Ç° ¿µÇâ¿¡ ´ëÇÑ ¿ì·Á°¡ Á¦±âµÇ°í ÀÖ½À´Ï´Ù. À̹ø ÆÒµ¥¹ÍÀº µðÁöÅÐ °Ç° ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» °¡¼ÓÈÇϰí, ź·ÂÀûÀ̰í ÀûÀÀ·Â ÀÖ´Â ¸¸¼ºÁúȯ °ü¸® Àü·«ÀÇ Çʿ伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
¼ºñ½º ºÐ¾ß´Â ½ÃÀå¿¡¼ À¯¸®ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºñ½º¿¡´Â Àå±âÀûÀÎ °Ç° »óÅ¿¡ ´ëóÇÏ´Â °³ÀÎÀÇ ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤µÈ ´Ù¾çÇÑ ÇコÄÉ¾î ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ¼ºñ½º¿¡´Â Áúº´ ¿¹¹æ ¹× ±³À°, Áø´Ü °Ë»ç, Ä¡·á °èȹ, ¾à¹° °ü¸®, »ýȰ½À°ü »ó´ã µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÇ·á ¼ºñ½º Á¦°øÀÚ´Â ¿ø°Ý ¸ð´ÏÅ͸µ, ¿ø°Ý ÀÇ·á »ó´ã, ¸¸¼ºÁúȯÀ» È¿°úÀûÀ¸·Î ÃßÀûÇÏ°í °ü¸®Çϱâ À§ÇÑ µ¥ÀÌÅÍ ±â¹Ý °³ÀÔ°ú °°Àº ±â¼úÀ» Ȱ¿ëÇÏ¿© ȯÀÚ Áß½ÉÀÇ Ä¡·á¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Áö¿ø ±×·ì°ú Á¤½Å °Ç° ¼ºñ½ºµµ ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ Á¤¼Àû, ½É¸®Àû Ãø¸éÀ» ´Ù·ç´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.
´ç´¢º´ ºÐ¾ß´Â ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´Àº ±¤¹üÀ§ÇÑ À¯º´·ü°ú Á¾ÇÕÀûÀÎ °ü¸®ÀÇ Çʿ伺À¸·Î ÀÎÇØ ¸¸¼ºÁúȯÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ³ôÀº Ç÷´çÄ¡¸¦ Ư¡À¸·Î ÇÏ´Â ÀÌ ¸¸¼ºÁúȯÀº Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ, »ýȰ½À°ü Á¶Á¤, ±×¸®°í Á¾Á¾ ¾à¹° ¹× Àν¶¸° ¿ä¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿Í µðÁöÅÐ °Ç° ¼Ö·ç¼ÇÀº Ç÷´ç ¸ð´ÏÅ͸µ ±â±â, ´ç´¢º´ ±³À° ÇÁ·Î±×·¥, °³ÀÎ ¸ÂÃãÇü ½Ä´Ü ¹× ¿îµ¿ °èȹ, ¿ø°Ý °Ç° »ó´ã µî ´Ù¾çÇÑ ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ±× ¸ñÀûÀº ´ç´¢º´ ȯÀÚ°¡ ÀÚ½ÅÀÇ »óŸ¦ ´õ Àß °ü¸®Çϰí ÇÕº´Áõ À§ÇèÀ» ÁÙÀ̸ç Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖµµ·Ï µ½´Â °ÍÀÔ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì ½ÃÀåÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù¸¦ Æ÷ÇÔÇÑ ÀÌ Áö¿ªÀº °í·ÉÈ, »ýȰ½À°üº´ ¹× ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇØ Çõ½ÅÀûÀÎ Áúº´ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á, ¿þ¾î·¯ºí ±â±â, ÀüÀÚ ÀÇ·á ±â·ÏÀÇ Ã¤ÅÃÀÌ È®´ëµÇ¸é¼ ¿ø°Ý ¸ð´ÏÅ͸µ°ú °³Àκ° ¸ÂÃã Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì Áö¿ª¿¡¼´Â Á¤ºÎ Á¤Ã¥°ú ÀÇ·á ±ÔÁ¦°¡ ¸¸¼ºÁúȯ °ü¸® ÇÁ·Î±×·¥ °³¹ß ¹× ½ÃÇàÀ» Àå·ÁÇÏ´Â °æ¿ì°¡ ¸¹¾Æ ȯÀÚ °á°ú °³¼±°ú ¸¸¼ºÁúȯÀÇ °æÁ¦Àû ¿µÇâ °¨¼Ò¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÇ·á Çõ½ÅÀÇ ºñ¿ÁÇÑ Åä¾çÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº Àα¸°¡ ¸¹°í, Áß»êÃþÀÌ Áõ°¡Çϰí, ¶óÀÌÇÁ½ºÅ¸ÀÏÀÌ º¯ÈÇÏ¸é¼ ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, È£Èí±â Áúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿Í ±â¼ú ±â¾÷µéÀº Áúº´ ¿¹¹æ, ¸ð´ÏÅ͸µ ¹× Ä¡·á¸¦ À§ÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Àû±ØÀûÀ¸·Î µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼ºñ½º, ¸ð¹ÙÀÏ °Ç° ¾Û, ¿ø°Ý ¸ð´ÏÅ͸µ ÀåÄ¡´Â ƯÈ÷ Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡¿¡¼ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÀÇ·á Á¢±Ù¼ºÀ» °³¼±Çϱâ À§ÇÑ Á¤ºÎÀÇ ³ë·Â°ú ¸¸¼ºÁúȯ °ü¸®ÀÇ Á߿伺¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Chronic Disease Management Market is accounted for $6.3 billion in 2023 and is expected to reach $15.6 billion by 2030 growing at a CAGR of 13.8% during the forecast period. The Chronic Disease Management Market is the healthcare sector dedicated to addressing long-term, non-communicable health conditions such as diabetes, heart disease, and cancer. It involves a range of strategies and technologies aimed at preventing, monitoring, and treating these conditions to improve patients' quality of life. Its uses include remote patient monitoring, personalized treatment plans, and data-driven interventions.
According to NCBI, chronic diseases account for about 60% of deaths and 43% of the global disease burden.
As demographics shift towards an older populace, there is a heightened prevalence of chronic diseases, as many of these conditions become more common with age. This demographic trend places a substantial burden on healthcare systems and resources, necessitating enhanced disease management strategies. The demand for specialized care, preventive measures, and long-term support for chronic illnesses is on the rise, fostering the development of tailored healthcare solutions and technologies. Addressing the healthcare needs of the aging population not only improves their quality of life but also drives the growth of the chronic disease management market as it becomes increasingly essential in providing effective and efficient care.
Developing and deploying cutting-edge technologies, remote monitoring systems, and personalized treatment solutions often require substantial financial investments. Healthcare organizations and providers may be constrained by budget limitations and face challenges in allocating resources for the adoption of expensive technologies. Additionally, these costs can translate to higher expenses for patients, limiting their access to advanced chronic disease management. The financial burden may also deter smaller healthcare facilities and underserved regions from offering comprehensive disease management services, potentially exacerbating health disparities. Mitigating these cost barriers is essential to ensure equitable access to effective chronic disease management solutions.
Many governments worldwide are recognizing the economic and public health implications of rising chronic disease burdens. As a result, they are implementing policies that encourage the development and adoption of innovative disease management solutions. Incentives may include financial support, reimbursement programs, and regulatory frameworks that promote the integration of technology and telehealth into healthcare systems, making it easier for providers to offer effective chronic disease management services. These policies not only stimulate market growth but also contribute to better access to care, reduced healthcare costs, and improved patient outcomes, creating a win-win scenario for healthcare stakeholders and patients alike.
While regulations are essential for ensuring patient safety and data security, an overly complex and restrictive regulatory environment can impede innovation and hinder the rapid development and deployment of new technologies and solutions for managing chronic diseases. Compliance challenges can increase the time and cost of bringing products to market, creating barriers for businesses and healthcare providers. Additionally, navigating a complex regulatory landscape may deter some companies from entering the market, limiting competition and potentially limiting the availability of advanced chronic disease management solutions, ultimately impacting patient care and healthcare system efficiency.
The COVID-19 pandemic has had a profound impact on the Chronic Disease Management Market. With healthcare systems focused on responding to the pandemic, there has been a disruption in routine chronic disease care. Telemedicine and remote monitoring solutions gained prominence to minimize in-person visits and reduce exposure risks for vulnerable populations. However, the diversion of resources towards pandemic-related efforts and delays in routine screenings and treatments has led to a potential increase in unmanaged chronic conditions, which may have long-term health implications. The pandemic has accelerated the adoption of digital health solutions while highlighting the need for resilient and adaptable chronic disease management strategies.
The services segment is expected to have lucrative growth in the market. Services in the market encompass a wide range of healthcare offerings tailored to address the needs of individuals dealing with long-term health conditions. These services include disease prevention and education, diagnostic testing, treatment planning, medication management, and lifestyle counseling. Healthcare providers offer patient-centered care by leveraging technology for remote monitoring, telehealth consultations, and data-driven interventions to track and manage chronic diseases effectively. Support groups and mental health services also play a vital role in addressing the emotional and psychological aspects of living with a chronic condition.
The diabetes segment is anticipated to witness the fastest CAGR growth during the forecast period. Diabetes is a central focus in the chronic disease, given its widespread prevalence and the need for comprehensive management. This chronic condition, characterized by high blood sugar levels, requires ongoing monitoring, lifestyle adjustments, and often medication or insulin therapy. Healthcare providers and digital health solutions offer a range of services, including glucose monitoring devices, diabetic education programs, personalized dietary and exercise plans, and telehealth consultations. The goal is to empower individuals with diabetes to better manage their condition, reduce the risk of complications, and improve their overall quality of life.
During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region encompasses the United States and Canada, where the aging population, lifestyle-related diseases, and the rising burden of chronic illnesses drive the demand for innovative disease management solutions. The adoption of telehealth, wearable devices, and electronic health records is widespread, enabling remote monitoring and personalized care. Additionally, government policies and healthcare regulations in North America often encourage the development and implementation of chronic disease management programs, making it a fertile ground for healthcare innovation, with a focus on improving patient outcomes and reducing the economic impact of chronic diseases.
Asia Pacific is projected to have the highest CAGR over the forecast period. The region's significant population, rising middle class and lifestyle changes have led to an increasing prevalence of chronic diseases like diabetes, cardiovascular conditions, and respiratory disorders. Healthcare providers and technology companies are actively introducing innovative solutions for disease prevention, monitoring, and treatment. Telehealth services, mobile health apps, and remote monitoring devices are gaining traction, especially in countries like China and India. Government initiatives to improve healthcare access and the growing awareness among patients about the importance of managing chronic conditions contribute to the market's expansion.
Some of the key players in Chronic Disease Management market include: HealthSmart Holdings, Inc., Vivify Health, Inc, Medecision, Inc., Pegasystems Inc., Allscripts Healthcare Solutions, Inc., Altruista Health, AxisPoint Health, Epic Corporation Inc., TriZetto Corporation, EXL Healthcare, ZeOmega Inc. and Health Catalyst.
In January 2023, MedStar Health and Zephyr AI, Inc. a start-up specializing in precision medicine technology announced their partnership to work to improve outcomes for chronic diseases, beginning with type 2 diabetes (T2D).
In October 2022, Enli Health Intelligence, a supplier of digital solutions for population health management, was acquired by Cedar Gate Technologies. With the addition of cohort, population, and patient management technologies, risk & quality indicators, gaps in care identification, and patient outreach opportunities, Cedar Gate's enterprise value-based care platform was intended to be expanded for improved outcomes and long-term financial viability.